Licensing status

Publication and contact information

Drug platforms

Adoptive cell therapy using mutation-specific, CD4+ T cells in epithelial cancer

A single-patient study suggests adoptive cell therapy using tumor mutation-specific, CD4+ T cells could help treat epithelial cancer. Ex vivo, patient dendritic cells were transfected with RNAs representing 26 different patient-specific cancer mutations identified via whole-exome sequencing and then cocultured with patient tumor-infiltrating lymphocytes (TILs). Patient CD4+ T cells specifically recognized dendritic cells presenting an ErbB2 interacting protein (ERBB2IP) antigen with an E805G mutation. In the patient, adoptive transfer of about 10 billion ERBB2IPE805G mutation-specific, CD4+ T cells led to tumor regression that peaked at 7 months and disease stabilization for about 13 months. Next steps include evaluating mutations in additional cancers that would be recognized by T cells and amenable for use in mutation-specific, CD4+ T cell therapy.

SciBX 7(22); doi:10.1038/scibx.2014.658
Published online June 5, 2014

Patent application filed; licensing status unavailable

Tran, E. et al. Science; published online May 9, 2014;
Contact: Steven A. Rosenberg, National Cancer Institute, Bethesda, Md.